Plain-English translation of NCT06953479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a simplified hepatitis C treatment approach called sofosbuvir/velpatasvir (Epclusa) can work effectively in jail settings. Normally, hepatitis C treatment requires frequent blood tests and close monitoring, but this study simplifies that process so people can receive the full 12-week course without lab monitoring during treatment. The study also pairs the medication with support from Community Health Workers who help people stay on track with their medication after they're released.
Many people with hepatitis C in the jail and prison system never receive treatment because the usual approach is complicated and requires frequent appointments. This trial aims to show that the medication works just as well with fewer barriers, so more people can be cured of hepatitis C while incarcerated or soon after release.
You likely qualify if…
You likely don't qualify if…
You would receive the full 12-week course of the medication while in jail without needing frequent blood tests during treatment. A Community Health Worker would check in with you before and after your release to help you take the medication as prescribed, answer questions, and arrange follow-up testing to confirm you're cured. You may also be asked to participate in interviews about your experience with the program to help researchers improve it for others.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States